Hypofractionated and accelerated radiotherapy with amifostine cytoprotection (HypoARC): A new concept in radiotherapy and encouraging results in breast cancer

Seminars in Oncology

Volumn 29, Issue 6 SUPPL. 19, 2002, Pages 42-46

  Koukourakis, Michael I ^a,b  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^b Tumour/Angiogenesis Research Group   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; EPIRUBICIN; FLUOROURACIL; PROTEIN P53;

APOPTOSIS; ASTHENIA; BREAST CANCER; CANCER RECURRENCE; CANCER SURVIVAL; CELL PROTECTION; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEVER; HUMAN; HYPOTENSION; INTERSTITIAL PNEUMONIA; LUNG TOXICITY; MULTIMODALITY CANCER THERAPY; NEUROTOXICITY; ONCOGENE C ERB; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RADIOSENSITIVITY; RASH; SKIN EXFOLIATION; SKIN TOXICITY; TOXICITY; TREATMENT OUTCOME; VOMITING;

AMIFOSTINE; APOPTOSIS; BREAST NEOPLASMS; CELL HYPOXIA; CLINICAL TRIALS; COMBINED MODALITY THERAPY; CYTOPROTECTION; DOSE FRACTIONATION; HUMANS; RADIATION INJURIES; RADIATION-PROTECTIVE AGENTS;

EID: 0036984882     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2002.37359     Document Type: Conference Paper

References (24)

1. Withers HR: Biological basis for altered fractionation schemes. Cancer 55:2086-2095, 1985
2. Fowler JF: Intervals between multiple fractions per day. Differences between early and late reactions. Acta Oncol 27:181-183, 1988
3. Macejewski B, Taylor JM, Wither HR: Alpha/beta and the importance of the size of dose per fraction for late complications in the supraglottic larynx. Radiother Oncol 7:323-326, 1986
4. Fowler J, Chappell R, Ritter M: Is α/β for prostate tumors really low? Int J Radiat Oncol Biol Phys 50:1021-1031, 2001
5. Chapman JD, Gillespie CJ, Reuvers AP, et al: The inactivation of Chinese Hamster cells by X-rays: The effect of chemical modifiers on single and double-events. Radiat Res 64:365-375, 1975
6. Skarlatos J, Kosma L, Koukourakis M, et al: Hypofractionated radiotherapy with concurrent 5-fluorouracil radiosensitisation for recurrent or locally advanced colorectal cancer. A phase II study. Int J Colorectal Dis 11:206-210, 1996
7. Zambatis C, Skarlatos J, Koukourakis M, et al: High dose hypofractionated radiotherapy with concomitant 5-fluorouracil in the treatment of advanced sarcomas of the bone. A pilot study. Sarcoma 2:25-28, 1998
8. Kosma L, Koukourakis M, Skarlatos J, et al: Hypofractionated radiotherapy with 5-fluorouracil radiosensitization for locally "far advanced" breast cancer. Am J Clin Oncol 20:562-566, 1997
9. Withers HR, Taylor JMG, Maciejewski B: The hazards of accelerated tumor clonogene repopulation during radiotherapy. Acta Oncol 27:131-146, 1998
10. Dische S, Saunders M, Barrett A, et al: A randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer. Radiother Oncol 44:123-136, 1997
11. Saunders M, Dische S, Barrett A, et al: Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: A randomized multicentre trial. CHART Steering Committee. Lancet 350:161-165, 1997
12. Tubiana M, Dutreix J, Wambersie A, et al: Hypoxic cells and their importance in radiotherapy, in Tubiana M, Dutreix J, Wambersie A, et al (eds): Introduction to Radiobiology. London, Taylor & Francis, 1990, pp 210-224
13. Dobrowsky W, Naude J: Continuous hyperfractionated accelerated radiotherapy with/without mitomycin C in head and neck cancers. Radiother Oncol 57:119-124, 2000
14. Fletcher GH: Hypofractionation: Lessons from complications. Radiother Oncol 20:10-15, 1991
15. Koukourakis MI: Amifostine in clinical oncology: Current use and future applications. Anticancer Drugs 13:181-209, 2002
16. Koukourakis MI, Yannakakis D: High dose daily amifostine and hypofractionated intensively accelerated radiotherapy for locally advanced breast cancer. A phase I/II study and report on early and late sequellae. Anticancer Res 21:2973-2978, 2001
17. Koukourakis MI, Giatromanolaki A, Kouroussis C, et al: Hypofractionated and accelerated radiotherapy with cytoprotection (HypoARC): A short, safe, and effective postoperative regimen for high-risk breast cancer patients. Int J Radiat Oncol Biol Phys 52:144-155, 2000
18. Koukourakis MI, Kyrias G, Kakolyris S, et al: Subcutaneous administration of amifostine during fractionated radiotherapy: A randomized phase II study. J Clin Oncol 18:2226-2233, 2000
19. Low SW, Bodis S, McClatchey A, et al: p53 status and the efficacy of cancer therapy in vivo. Science 266:807-810, 1994
20. Reed JC: Bcl-2 and regulation of cell death. J Cell Biol 124:1-6, 1994
21. Pietras RJ, Poen JC, Gallardo D, et al: Monoclonal antibody to HER-2/neu receptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Res 59:1347-1355, 1999
22. Koukourakis MI, Giatromanolaki A, Sivridis E, et al: Hypoxia inducible factor (HIF1α and HIF2α), angiogenesis and chemoradiotherapy outcome of squamous cell head and neck cancer. Int J Radiat Oncol Biol Phys 53:1192-1202, 2002
23. Koukourakis MI, Giatromanolaki A, Sivridis E, et al: Hypoxia-regulated carbonic anhydrase-9 (CA9) relates to poor vascularization and resistance of squamous cell head and neck cancer to chemoradiotherapy. Clin Cancer Res 7:3399-3403, 2001
24. Koukourakis MI, Giatromanolaki A, Kakolyris S, et al: Nuclear expression of human apurinic/apyrimidinic endonuclease (HAP1/Ref-1) in head and neck cancer is associated with resistance to chemo-radiotherapy and poor outcome. Int J Radiat Oncol Biol Phys 50:27-36, 2001